Kaopectate Liquid
NDC Package 55505-229-64
Package Information
Kaopectate (bismuth subsalicylate) liquids is shake well immediately before each useonly use pre-measured dose cupadults and children 12 years of age and older: 1 dose (30 mL) every hour as needed.do not exceed 4 doses (120 mL) in 24 hoursuse until diarrhea stops but not more than 2 dayschildren under 12 years: ask a doctordrink plenty of clear fluids to help prevent dehydration caused by diarrhea. This formulation utilizes a liquid delivery system. Marketed by Kramer Laboratories, this product is identified by NDC 55505-229 and is authorized under FDA application M008.
Identification & Billing
- RxCUI: 1043048 - Kaopectate Extra Strength 525 MG in 15 mL Oral Suspension, Reformulated Aug 2006
- RxCUI: 1043048 - bismuth subsalicylate 35 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006]
- RxCUI: 1043048 - Kaopectate 525 MG per 15 ML Oral Suspension, Reformulated Aug 2006
- RxCUI: 1043048 - Kaopectate Reformulated Aug 2006 35 MG/ML Oral Suspension
- RxCUI: 308763 - bismuth subsalicylate 1050 MG in 30 mL Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55505 - Kramer Laboratories
- 55505-229 - Kaopectate
- 55505-229-64 - 325 mL in 1 BOTTLE
- 55505-229 - Kaopectate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55505-229-64 identifies a specific commercial package of 325 ml in 1 bottle of Kaopectate, a human over the counter drug labeled by Kramer Laboratories. This liquid is formulated for oral use and contains bismuth subsalicylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kramer Laboratories on February 01, 2026. The current certification is valid through December 31, 2026.
How is this Kramer Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55505022964. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.